By Colin Kellaher
AstraZeneca PLC and Merck & Co. Monday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of two additional indications for the cancer drug Lynparza.
The drugmakers said one recommendation covers Lynparza as monotherapy for the treatment of adults with metastatic castration-resistant prostate cancer and BRCA1/2 mutations who have progressed following a prior therapy that included a new hormonal agent.
The second recommendation covers Lynparza as a first-line maintenance treatment in combination with bevacizumab for HRD-positive advanced ovarian cancer.
The indications now await approval from the European Commission, which generally follows the CHMP's recommendations.
AstraZeneca and Merck in 2017 formed a collaboration to co-develop and co-commercialize Lynparza for multiple cancer types.
Write to Colin Kellaher at email@example.com